Join the Prostate Cancer group to help and get support from people like you.
Prostate Cancer News (Page 7)
Related terms: Cancer, Prostate, Carcinoma of Prostate
FDA Approves Xtandi (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
TOKYO and NEW YORK, July 13, 2018 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and...
Sun Pharma Announces FDA Approval of Yonsa (abiraterone acetate) to Treat Metastatic Castration-Resistant Prostate Cancer
MUMBAI & PRINCETON, N.J. & KING OF PRUSSIA, Pa. May 23, 2018 --(BUSINESS WIRE)--Sun Pharmaceutical Industries Ltd. and includes its subsidiaries and/or associate companies) and Churchill...
Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
HORSHAM, PA, Feburary 8, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga (...
FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer
February 14, 2018 – The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that...
FDA Approves Axumin (fluciclovine F 18) Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
May 27, 2016 – The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men...
Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula
San Jose, Calif. - December 28, 2015 - Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel...
FDA Approves Xofigo for Advanced Prostate Cancer
May 15, 2013 – The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that...
FDA Expands Zytiga’s Use for Late-Stage Prostate Cancer
December 10, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate...
FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer
August 31, 2012 – The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or...
FDA Approves New Indications for Prolia (denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
THOUSAND OAKS, Calif., September 19, 2011, 2011 /PRNewswire/ – Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia (denosumab) as a...
FDA Approves Zytiga for Late-Stage Prostate Cancer
SILVER SPRING, Md., April 28, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Zytiga (abiraterone acetate) in combination with prednisone (a steroid) to treat...
Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review
Paris, France – June 17, 2010 – Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana (cabazitaxel) Injection in combination w...
FDA Approves Provenge - a Cellular Immunotherapy for Men With Advanced Prostate Cancer
SILVER SPRING, Md., April 29 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that...
FDA Approves Watson's Trelstar 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ – Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration (FDA) approval of Trelstar 22.5 mg (triptorelin pamoate for...
Ask a question
To post your own question to this support group, sign in or create an account.